Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Davis Polk Advises Penumbra, Inc. on Its $138 Million Initial Public Offering
Davis Polk advised Penumbra, Inc. on its SEC-registered initial public offering of 4,600,000 shares of common stock for an…
Davis Polk Wins Summary Judgment of Non-Infringement in Patent Litigation on Behalf of Transcend Medical, Inc.
Davis Polk represents Transcend Medical, Inc., an innovator in the field of Micro-Invasive Glaucoma Surgery, in a patent…
Davis Polk Advises Fujian Thai Hot Investment on Its Purchase of a Majority Interest in Alliance HealthCare Services
Davis Polk is advising Fujian Thai Hot Investment Co., Ltd in connection with its purchase of approximately 51.5% of the…
Seattle Genetics, Inc. $552 Million Equity Offering
Davis Polk advised the underwriters, in connection with an SEC-registered offering by Seattle Genetics, Inc. of 13,463,415…
Biogen Inc. $6 Billion Senior Notes Offering
Davis Polk advised the underwriters, in connection with the SEC-registered offering by Biogen Inc. of $1.5 billion principal…
Davis Polk Advises RoundTable Healthcare Partners on the Formation of Its Equity Fund IV and Capital Fund III
Davis Polk advised RoundTable Healthcare Partners (“RoundTable”) in connection with the formation of, and the sale of…
Global Blood Therapeutics, Inc. Initial Public Offering
Davis Polk advised the joint book-running managers in connection with the $138 million initial public offering of common…
Celgene $8.0 Billion Notes Offering
Davis Polk advised the joint book-running managers on an SEC-registered offering by Celgene Corporation of $8.0 billion…
Aimmune Therapeutics, Inc. $183.9 Million Initial Public Offering
Davis Polk advised the underwriters in connection with the $183.9 million initial public offering of Aimmune Technologies,…
Atara Biotherapeutics, Inc. $207 Million Follow-On Offering
Davis Polk advised the joint book-running managers in connection with the $207 million SEC-registered follow-on offering of…